Earnings Preview For Inogen

Inogen (NASDAQ:INGN) is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here’s what investors need…

Inogen (NASDAQ:INGN) is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here’s what investors need to know before the announcement.

Analysts estimate that Inogen will report an earnings per share (EPS) of $-0.64.

Inogen bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.18, which was followed by a 5.38% drop in the share price the next day.

Here’s a look at Inogen’s past performance and the resulting price change:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate -0.81 -0.57 -0.42 -0.37
EPS Actual -0.63 -0.57 -0.18 -0.02
Price Change % -5.38% -31.39% -5.06% -3.25%

eps graph

Stock Performance

Shares of Inogen were trading at $7.63 as of August 03. Over the last 52-week period, shares are down 72.62%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all earnings releases for Inogen visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Recap: Marathon Oil Q2 Earnings

Marathon Oil (NYSE:MRO) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings Marathon Oil beat estimated earnings by 2.33%, reporting an EPS of $1.32 versus an estimate of $1.29.

MRO

Read More

Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY

Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the

BRAXF